Biocartis to present BRAF liquid biopsy data at ASCO

Share this article

Biocartis (BCART), will today present liquid biopsy data from the BRAF mutation study at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The study, in collaboration with Prof. Bart Neyns from the University Hospital Brussels, showed that BRAF oncogene mutations can be diagnosed not only in the solid tumor samples but also in plasma from metastatic melanoma patients.

Biocartis’ Idylla™ is a fully automated molecular diagnostic platform suited to work with virtually any clinical sample. In the presented study, Biocartis developed a prototype system for the analysis of BRAF mutations in circulating tumor DNA (ctDNA) from plasma samples. The system integrates and fully automates extraction of ctDNA and powerful selective amplification enabling the sensitive detection of BRAF V600 mutations from 1 ml of plasma.

Read more about Idylla™ and the use of liquid biopsies for diagnostics in our soon to be published interview with Prof. Bart Neyns.